The Cox model results, including regression coefficients and HRs with their 95% CI.
| Variable | Coefficient (β) | Hazard ratio (HR) | 95% CI for HR | P-value |
|---|---|---|---|---|
| Age | 0.719 | 2.054 | 0.955–4.418 | 0.06 |
| Type of surgery | 1.059 | 2.884 | 1.277–6.513 | 0.01 |
| Lymph × treatment | –1.292 | 0.275 | 0.094–0.798 | 0.02 |
| Metastasis × grade | 1.960 | 7.101 | 3.349–15.057 | < 0.01 |
CI: confidence interval.
MAF: Data curation, Investigation, Software, Validation, Formal analysis, Visualization, Writing—original draft. FS: Data curation, Investigation, Formal analysis, Writing—original draft. HRM: Conceptualization, Methodology, Formal analysis, Validation, Writing—original draft, Writing—review & editing, Supervision, Project administration. MS: Investigation, Validation, Resources, Data curation, Writing—review & editing. AN: Investigation, Validation, Resources, Data curation, Writing—review & editing. MM: Conceptualization, Formal analysis, Validation, Writing—review & editing, Supervision, Project administration. All authors read and approved the final manuscript.
The authors declare that they have no conflicts of interest.
The survival prediction in the Triple-Negative Breast Cancer study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (Ethical code: IR.MUI.REC.1401.355).
Informed consent to participate in the study was obtained from all participants.
Not applicable.
The datasets analyzed during the current study are not publicly available due to ethical restrictions and institutional regulations imposed by the approving ethics committee.
Not applicable.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.